times more likely to discontinue treatment than werethose who started at a lower dose [15]. On the basis ofsimilar experiences, an acarbose study demonstrated thatthe proportion of subjects experiencing gastrointestinaldistress decreased from 41% at week 4 to 25% atweek 24 on a dosing regimen of 50 mg TID for theﬁrst 4 weeks, which was increased to a maintenancedose of 100 mg TID thereafter [16]. Dose-escalation isalso commonly used for other therapeutic classes such Copyright 2004 John Wiley & Sons, Ltd. Diabetes Metab Res Rev 2004; 20: 411–417.